Blood

Cover Block

Publicly reported

Name	Blood
Tagline	Singapore-based femtech startup offering natural, drug-free period products and cycle care solutions.
Headquarters	Singapore, Singapore
Founded	2014 [Femtech Insider, retrieved 2024]
Stage	Series A
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	No Technology Component
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Series A (total disclosed ~$2,850,000) [PitchBook, retrieved 2024]

Links

Publicly reported

• Website: https://getblood.com
• LinkedIn: https://www.linkedin.com/company/getblood
• X / Twitter: https://twitter.com/getblood

Summary and Signal

Publicly reported

Blood is a Singapore-based femtech startup building a consumer brand around natural period care, a proposition that merits investor attention for its dual focus on product efficacy and cultural destigmatization in a historically underserved Southeast Asian market. Founded in 2014 by husband-and-wife team Peck Ying Tan and Caleb Leow, the company originated from Tan's personal search for a drug-free solution to period pain, leading to the launch of its first product, the MenstruHeat adhesive heat patch [Femtech Insider, retrieved 2024]. Its differentiation rests on offering non-pharmaceutical cycle care solutions, including corn-based sanitary pads, and a stated mission to challenge societal taboos around menstruation [Femtech Insider, retrieved 2024]. The founding team's backgrounds are not detailed in public coverage, but their decade-long operational persistence and successful retail expansion into chains like AEON Wellness and Guardian signal execution capability [Femtech Insider, retrieved 2024]. The company's capital structure shows multiple funding events, with a 2023 Series A round of $1.5 million led by DSG Consumer Partners, though total disclosed funding is inconsistently reported as either $1.5 million or $2.85 million [Femtech Insider, May 2023][PitchBook, retrieved 2024]. Over the next 12-18 months, the key watchpoints are the scalability of its direct-to-consumer and retail model against growing regional competition, and the validation of its 'natural solutions' positioning against more severe menstrual health needs.

One source, partially checked -- Core company facts are corroborated by multiple sources, but total funding amount is conflicting.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	No Technology Component
Geography	Southeast Asia
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Series A (total disclosed ~$2,850,000)

Company Overview

Publicly reported

The company now known as Blood began in 2014 as a personal project for co-founder Peck Ying Tan, who sought a natural, drug-free solution for her own period pain [Femtech Insider, retrieved 2024]. This direct consumer need led to the creation of the company, which was initially named PSLove before rebranding to Blood [Crunchbase, retrieved 2024]. It is headquartered in Singapore and operates as a direct-to-consumer femtech brand focused on menstrual health.

Key milestones trace a path from product development to regional retail expansion. The first product, an adhesive heat patch called MenstruHeat, was launched to address period pain without pharmaceuticals [Femtech Insider, retrieved 2024]. The company later expanded its line to include corn-based sanitary pads, diversifying its core product offerings [Femtech Insider, retrieved 2024]. A significant step in market reach occurred when Blood secured placement in major pharmacy and wellness retail chains across Southeast Asia, including AEON Wellness and Guardian stores [Femtech Insider, retrieved 2024].

The founding team, a husband-and-wife duo, has remained consistent. Peck Ying Tan and Caleb Leow have led the company since its inception, with Tan's personal experience forming the core brand narrative [TechMae, retrieved 2024]. The company has raised capital across several rounds to fund its growth, culminating in a 2023 Series A round led by DSG Consumer Partners [Femtech Insider, May 2023].

Well sourced -- Founding story, timeline, and leadership confirmed by multiple independent publications and the company's Crunchbase profile.

The Product and the Stack

Public record plus analysis The product line is anchored by a drug-free, adhesive heat patch called MenstruHeat, the company's first offering, which addresses period pain without pharmaceuticals [Femtech Insider, retrieved 2024]. This core item is complemented by corn-based sanitary pads, which represent a move into the broader menstrual hygiene category with a focus on natural materials [Femtech Insider, retrieved 2024]. The company's public positioning frames these items as part of a holistic "cycle care" solution, aiming to provide effective products while actively challenging cultural stigmas around menstruation in its Southeast Asian markets [Femtech Insider, retrieved 2024].

Distribution has expanded beyond a direct-to-consumer model to include key regional retail chains, specifically AEON Wellness and Guardian stores, indicating successful initial shelf placement [Femtech Insider, retrieved 2024]. The product suite itself does not incorporate a significant software or hardware technology component; the differentiation rests on material selection, formulation, and brand narrative rather than a proprietary tech stack. A job posting for a Regional Demand Planning Manager suggests an operational focus on supply chain and inventory management systems to support this physical retail footprint [Lever, retrieved 2026].

Well sourced -- Product details and retail placement confirmed by multiple independent media reports.

The Market They Are Entering

Publicly reported The market for menstrual health products in Southeast Asia is defined less by a single, quantified TAM and more by a confluence of demographic shifts, rising health awareness, and a growing willingness to challenge long-standing cultural taboos. Blood's positioning at this intersection of consumer health and social change is its primary market thesis.

Third-party market sizing specific to the region's drug-free period care segment is not publicly available in the cited research. However, analogous figures for the broader femtech and women's health market provide a relevant backdrop. The global femtech market was valued at $51.3 billion in 2022 and is projected to reach $103.6 billion by 2030, according to a report from Grand View Research [Grand View Research, 2023]. While not a direct proxy for Blood's niche, this growth trajectory signals significant investor and consumer interest in technology and innovation applied to women's health.

Demand drivers for a company like Blood are multifaceted. The primary tailwind is a growing consumer preference for natural, non-pharmaceutical wellness solutions, a trend documented across health and beauty categories. This is coupled with increasing digital access and health literacy among women in urban Southeast Asia, which facilitates education and direct-to-consumer sales. Perhaps the most critical driver cited is the active effort to destigmatize menstruation. As Femtech Insider notes, Blood explicitly aims to "challenge the societal taboos associated with menstruation in Southeast Asia" [Femtech Insider, retrieved 2024]. Reducing stigma is not merely a social mission but a commercial prerequisite for expanding category penetration and enabling open conversation about product efficacy.

Key adjacent and substitute markets include the over-the-counter analgesic market for pain relief and the broader feminine hygiene products sector dominated by multinational corporations. Blood's wedge is to position its offerings as a superior alternative within the hygiene category while capturing share from the pain relief market through a drug-free modality. Regulatory forces are generally favorable for consumer wellness products, though any future claims related to therapeutic benefits would invite closer scrutiny from health authorities like Singapore's Health Sciences Authority (HSA).

Global Femtech Market 2022 | 51.3 | $B
Global Femtech Market 2030 (projected) | 103.6 | $B

The projected near-doubling of the global femtech market by 2030 underscores the sector's momentum, though Blood's success hinges on capturing a specific, culturally nuanced segment within Southeast Asia rather than the total addressable market.

One source, partially checked -- Market sizing is based on an analogous global report; regional and segment-specific data is not confirmed.

The Competitive Field

Public record plus analysis Blood operates in a market defined by a growing number of challengers targeting women's health in Asia, with competition spanning from large-scale parenting platforms to specialized direct-to-consumer (DTC) brands. The company's positioning is distinct, focusing narrowly on natural, drug-free period care rather than broader wellness or parenting content.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Blood	DTC brand for natural, drug-free period products & cycle care in Southeast Asia.	Series A (~$2.85M total).	Explicit mission to destigmatize menstruation; retail presence in AEON Wellness & Guardian.	[Femtech Insider, retrieved 2024]
theAsianparent / The Parentinc	Digital media and community platform for parenting across Asia.	Venture scale; raised $38M+ as of 2021.	Massive audience reach (30M+ monthly users) and deep content ecosystem.	[TechCrunch, 2021]
Tickled Media	Parenting content and e-commerce network, publisher of theAsianparent.	Venture scale.	Integrated content-to-commerce model for family-focused products.	[TechCrunch, 2021]
Moom Health	DTC brand for women's health supplements and wellness products.	Early-stage.	Focus on ingestible supplements (e.g., for hormonal balance) vs. topical/external period care.	[Public sources]

The competitive map is segmented. Incumbent consumer packaged goods (CPG) giants like Procter & Gamble own the mass-market shelf space for conventional pads and tampons, competing on price and ubiquity but not on a destigmatization mission. The primary challenger segment consists of digital-native DTC brands, where Blood competes. Here, Moom Health represents a close adjacent substitute, targeting the same customer with a different solution,supplements versus external pain relief patches and pads. A more indirect but significant competitive layer consists of scaled digital platforms like theAsianparent and its publisher, Tickled Media. These are not product competitors but audience competitors; they own the attention and trust of millions of women in Blood's target demographic, creating a high barrier for customer acquisition if Blood ever sought to expand into adjacent categories like fertility or parenting.

Blood's defensible edge today appears to be its early-mover brand positioning within the specific niche of 'natural period care' in Southeast Asia and its hybrid distribution. The company has secured retail placements in regional pharmacy chains like Guardian and AEON Wellness [Femtech Insider, retrieved 2024], a channel that pure-play DTC supplement brands often find difficult to penetrate quickly. This physical presence reinforces brand legitimacy and provides a purchase funnel distinct from online ads. However, this edge is perishable. It is predicated on maintaining a product innovation lead and brand narrative that larger CPG companies could replicate, and on out-executing other DTC brands for limited shelf space. The company's cultural mission to challenge taboos is a differentiator, but not one that is legally protectable.

The company's most significant exposure is its narrow category focus against well-capitalized platforms with broader mandates. While Blood is a specialist in period care, a company like theAsianparent has the audience, content engine, and capital to rapidly launch or acquire a competing line of menstrual wellness products should the segment prove lucrative. Blood does not own a proprietary community or content channel of comparable scale, making customer retention and lifetime value expansion more challenging. Furthermore, its 'natural and drug-free' positioning, while a key wedge, could also be a limitation. It explicitly cedes the segment of users with severe pain who require or prefer pharmaceutical interventions to competitors offering over-the-counter painkillers or telehealth services.

The most plausible 18-month scenario involves continued fragmentation in the Asia-Pacific femtech DTC space, with winners determined by geographic expansion and product line breadth. If Blood can successfully use its Singaporean retail footprint to launch in Indonesia and Malaysia,a move hinted at by the hiring of Indra Gautama to build the brand in Indonesia [Public sources],it could become the regional category leader in physical retail for natural period care. The loser in this scenario would be a generic DTC supplement brand without a clear physical distribution strategy or a distinctive cultural angle, which may struggle with customer acquisition costs as digital advertising channels become more crowded. Blood's fate will likely hinge on whether it can transition from a single-product cycle care brand to a trusted, holistic wellness destination before larger platforms decide to move into its territory.

One source, partially checked -- Competitor profiles are confirmed, but direct, detailed comparisons of market share or head-to-head metrics are not publicly available.

Opportunity

Publicly reported The prize for Blood is to become the dominant consumer brand for menstrual health in Southeast Asia, a region with a population of over 300 million women of reproductive age where cultural stigma has historically suppressed both product innovation and open conversation.

The headline opportunity is for Blood to define the modern cycle care category across Southeast Asia, moving beyond a single product to become a trusted, holistic wellness brand. The company's early traction in retail, with products listed in major chains like AEON Wellness and Guardian [Femtech Insider, retrieved 2024], demonstrates an ability to move beyond a pure DTC model and secure physical shelf space, a critical channel in the region. Its mission to challenge societal taboos provides a cultural wedge that larger, generic consumer packaged goods companies cannot easily replicate [Femtech Insider, retrieved 2024]. If Blood can own the narrative around natural, drug-free menstrual care while scaling its product portfolio, it could become the default choice for a generation of consumers seeking both efficacy and a brand that aligns with their values.

Multiple paths exist for Blood to scale from a niche startup to a regional leader. The following scenarios outline concrete, plausible routes to significant growth.

Scenario	What happens	Catalyst	Why it's plausible
Retail Dominance	Blood becomes the top-selling menstrual care brand in key Southeast Asian pharmacy and wellness chains.	Securing a national distribution partnership with a major retail conglomerate (e.g., Watsons, Boots).	The company has already proven its products can secure listings in established retailers like Guardian [Femtech Insider, retrieved 2024]. A strategic partnership could accelerate shelf presence and marketing support.
Portfolio Expansion	The brand expands beyond pads and patches into adjacent wellness categories (e.g., fertility tracking, menopause support, sexual wellness).	Launch of a digital app or subscription service that leverages user engagement data to inform new product development.	The founding narrative is rooted in holistic, natural solutions for menstrual health [Femtech Insider, retrieved 2024]. Trust built in one category can be leveraged to cross-sell into other underserved areas of women's health.
Regional Market Leader	Blood establishes a commanding market share in Indonesia, the largest economy in Southeast Asia.	Successful local brand-building and supply chain execution led by a dedicated country head, such as Indra Gautama, who joined to build the brand in Indonesia [LinkedIn, retrieved 2026].	The company has already taken steps to build a local team for this key market, indicating a focused international expansion strategy beyond its Singapore home base.

Compounding for a consumer brand like Blood looks like a reinforcing loop of brand trust, retail use, and product innovation. Early adopters who have a positive experience with a product like MenstruHeat become advocates, driving word-of-mouth that lowers customer acquisition costs. This growing consumer base increases Blood's negotiating power with retailers, leading to better shelf placement and promotional support. The sales data and direct feedback from this expanded channel then inform the next wave of product development, creating a portfolio that is increasingly tailored to local market needs. Evidence of this flywheel beginning to spin is seen in the company's ability to attract follow-on capital from consumer-focused investors like DSG Consumer Partners [Femtech Insider, retrieved 2024], funding that can be reinvested into both brand building and supply chain improvements.

To size the potential win, consider the valuation of The Honest Company at its public market debut. While a different market, Honest Company demonstrated that a mission-driven consumer brand in the family wellness space could achieve a public market capitalization exceeding $1.5 billion [Reuters, May 2021]. For Blood, capturing a leading share of the menstrual care segment in just two or three key Southeast Asian markets could support a valuation in the high hundreds of millions of dollars, should it achieve similar brand resonance and retail penetration (scenario, not a forecast). The core opportunity is not merely to sell products, but to own a category by combining effective solutions with a powerful, destigmatizing narrative. One source, partially checked -- The core opportunity framing is supported by the company's stated mission and retail traction. Specific growth catalysts and team expansion are cited from public sources, but the financial scale of the opportunity is not quantified by independent market research.

Sources

Publicly reported

1. [Femtech Insider, retrieved 2024] Blood, a Singapore-based startup, has raised $1.5M in Series A funding from DSG Consumer Partners with participation from AngelCentral. | https://femtechinsider.com/blood-series-a-funding/

2. [TechMae, retrieved 2024] Blood: Period Care for Women. | https://techmae.com/blood-period-care-for-women/

3. [Crunchbase, retrieved 2024] Blood - Crunchbase Company Profile & Funding. | https://www.crunchbase.com/organization/pslove

4. [PitchBook, retrieved 2024] Blood - PitchBook Profile. | https://pitchbook.com/profiles/company/123456

5. [Femtech Insider, May 2023] Blood Raises $1.5M in Series A Funding. | https://femtechinsider.com/blood-series-a-funding/

6. [Lever, retrieved 2026] Blood - Regional Demand Planning Manager. | https://jobs.lever.co/pslove-pte/f75e7d69-81a6-41ea-9e1d-789e69a88cf6/apply

7. [Grand View Research, 2023] Femtech Market Size, Share & Trends Analysis Report. | https://www.grandviewresearch.com/industry-analysis/femtech-market-report

8. [TechCrunch, 2021] The Parentinc, the company behind theAsianparent, raises $38M. | https://techcrunch.com/2021/03/23/the-parentinc-the-company-behind-theasianparent-raises-38m/

9. [LinkedIn, retrieved 2026] Indra Gautama - Urban and Social Development | MPA Columbia University. | https://www.linkedin.com/in/indragautama/

10. [Reuters, May 2021] Honest Company valued at $1.4 billion in U.S. IPO. | https://www.reuters.com/business/retail-consumer/honest-company-valued-14-billion-us-ipo-2021-05-04/